CNS - Tysabri

Our second project in MS focuses on patients receiving Tysabri® (natalizumab), a treatment which has been associated with a rare but serious side effect. We seek to identify early markers of Tysabri efficacy and side effects to aid in patient management. We are currently collecting samples and expect to have sufficient numbers to initiate the discovery phase of this project in the fourth quarter of 2007.